Soon-Shiong’s NantHealth tanks on STAT report of self-dealing; Bioversys, Aptuit forge antibiotic collab; Helix gets new CEO
→ STAT reported that biotech billionaire Patrick Soon-Shiong used a $12 million “gift” to the University of Utah as a carefully disguised boost to his cancer business, steering $10 million of that back into his hands under a contract that has raised questions about the way the money was handled. And the report has taken a big bite out of the share price of NantHealth $NH, which dropped 23%.
→ Basel-based Bioversys AG and Aptuit launched a joint collaboration aimed at the discovery of novel targets and molecules for Gram-negative bacteria.
→ Toronto-based Helix BioPharma has recruited a new CEO. CSO Heman Chao is adding the CEO title to his job description while Sven Rohmann will be chairman of the board as well as a strategic adviser.
→ San Francisco-based Velano Vascular has raised $17 million as it starts commercialization work on new, needle-free tech for drawing blood in hospitals.